类风湿关节炎患者起始糖皮质激素联合csDMARDs的减停动态轨迹:2009-2020年真实世界数据
该研究基于真实世界纵向队列,纳入207例起始糖皮质激素联合csDMARDs的类风湿关节炎患者,评估激素减量与停用的动态轨迹。中位随访38.6个月期间124例停用激素,中位停药时间27个月,停药后6个月内79.1%维持无复发,但停药时间远未达到指南推荐时间框架。
要点
- 起始泼尼松龙中位剂量10mg/天,前6个月减半,至48个月减至零。
- 激素停用的累积概率在6个月、1年、2年、3年分别为9.7%、26.6%、48.0%、58.6%。
- 停药后6个月内79.1%(91/115)患者维持无复发。
核心结论
- 在真实世界实践中,RA患者起始GC联合csDMARDs后停用GC可行且疾病活动度控制良好,多数无短期复发,但停药时间远未达到推荐时间框架,提示真实实践与现行指南存在差距。
研究设计与样本
- 研究使用Treat-to-TARget in RA纵向真实世界队列数据,纳入起始GC并同时使用csDMARDs的RA患者,评估GC剂量与疾病活动度变化,采用Kaplan-Meier分析GC停用率并分析停药后6个月内复发情况。
主要发现
- 共纳入207例RA患者,中位随访38.6个月期间124例停用GC。
- 起始泼尼松龙中位剂量10(5-10)mg/天,前6个月降低50%,之后减速,至48个月减至零。
- GC停用累积概率在6个月、1年、2年、3年分别为9.7%、26.6%、48.0%、58.6%,中位停药时间27个月。
- 在110例DMARD初治患者中,相应累积概率分别为12.7%、30.0%、50.9%、60.6%,中位停药时间24个月。
- 124例停用GC患者中28.2%记录了添加其他csDMARDs或增加伴随csDMARDs,约半数在停药时处于临床缓解;停药后6个月内79.1%(91/115)维持无复发。
临床怎么用
- 真实世界中RA患者起始GC联合csDMARDs后可按轨迹减停GC,多数停药后6个月内无复发,但需注意停药时间可能远长于指南推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering and discontinuation in patients with rheumatoid arthritis (RA) commencing GC with concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODS: We used data from longitudinal real-world Treat-to-TARget in RA cohort. Patients with RA who started GC and contaminant csDMARDs therapy were included. The changes in GC dose and disease activity were evaluated. GC discontinuation rate was analysed using Kaplan-Meier analysis. The relapse profile within 6 months after GC discontinuation was also analysed. RESULTS: A total of 207 patients with RA were included. During a median follow-up of 38.6 months, 124 patients discontinued GC. The median prednisolone dose of 10 (5-10) mg/day at initiation was reduced by 50% in the first 6 months and then more slowly, to zero by 48 months eventually. The cumulative probabilities of GC discontinuation were 9.7%, 26.6%, 48.0% and 58.6% at month 6, years 1, 2 and 3, with calculated median time to GC cessation of 27 months. In 110 DMARD-naïve patients, the corresponding cumulative probabilities of GC discontinuation were, respectively, 12.7%, 30.0%, 50.9% and 60.6%, with calculated median time to GC cessation of 24 months. Of the 124 patients who discontinued GC, adding other csDMARDs or concomitant csDMARDs increment was documented in 28.2% of them. Approximately half of 124 patients were in clinical remission at GC discontinuation. Within 6 months after GC withdrawal, 79.1% (91/115) of patients maintained relapse free. CONCLUSIONS: In patients with RA commencing GC besides csDMARDs, GC is feasibly discontinued with favourable control of disease activity in real-life setting, mostly without short-term flare. But the withdrawal time is far from reaching the recommended time frame, indicating the gap between real-world practice and current guidelines.
引用
- Xie W, Huang H, Li G, et al. Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. Ann Rheum Dis. 2021. PMID: 33811037. doi:10.1136/annrheumdis-2021-220112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。